Next Generation Ultrasound: An Evolution in Diagnosis and Therapy - Upcoming Frost & Sullivan Web Conference
By Frost Sullivan, PRNEWednesday, February 24, 2010
LONDON, February 25, 2010 - Exposure to radiation from imaging equipment is constantly subjected to
scrutiny from regulatory authorities. Ultrasound poses no radiation threat
and is constantly further developed to accentuate primary and secondary
diagnosis. The next wave in ultrasound technology will witness advancements
in Elastography and Contrast Enhanced Ultrasound (CEUS) for diagnosis. High
intensity focused ultrasound (HIFU) is also emerging to treat pathologies
that usually require surgical intervention.
(Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
In its upcoming web conference taking place on Thursday, 4th March 2010,
at 3 p.m. GMT Frost & Sullivan will focus on the Next Generation Ultrasound
Market in Europe. Research Analyst, Shriram Shanmugham, will present an
analysis of advancements such as High Intensity Focused Ultrasound for
therapy and contrast enhanced ultrasound for diagnosis.
To participate in this complimentary briefing, please email Katja Feick
at katja.feick@frost.com with your full contact details. Upon receipt of the
above information, a registration link will be e-mailed to you. You may also
register to receive a recorded version of the briefing at anytime by
submitting the aforementioned contact details.
This briefing will benefit product managers, R&D/product development
engineers, vice presidents for R&D, and CEOs who intend to acquire smaller
companies with a viable technology application. Many of the therapeutic
ultrasound companies are financed by venture capitals, and this briefing will
therefore benefit other VCs interested in investing in the ultrasound sector
in the long term.
"Affordability, mobility, cost and no safety threats are factors that
make ultrasound a worthy proposition for investment in hospitals," concludes
Mr. Shanmugham. "While the market for ultrasound is mature, advancements in
technology that address both diagnosis and therapy will trigger a niche
sector for growth in the ultrasound market over the next seven to ten years."
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best-in-class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best-practice models to
drive the generation, evaluation, and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from 40 offices on six continents. To join our Growth Partnership,
please visit www.frost.com.
Contact: Katja Feick Corporate Communications - Europe P: +49-(0)-69-7703343 E: katja.feick@frost.com www.frost.com Twitter: twitter.com/frost_sullivan
Katja Feick of Frost & Sullivan Corporate Communications - Europe, +49-(0)-69-7703343, katja.feick at frost.com
Tags: February 25, Frost & Sullivan, ireland, London, United Kingdom